Amneal receives U.S. FDA approval for albuterol sulfate inhalation aerosol

Amneal Pharmaceuticals (AMRX) announced that the U.S. Food and Drug Administration, FDA, has approved the Company’s albuterol sulfate inhalation aerosol. The product is the generic equivalent of PROAIR HFA, a registered trademark of Teva Respiratory. This approval follows the Company’s FDA approval of its beclomethasone dipropionate inhalation aerosol, a generic equivalent of QVAR, further advancing Amneal’s entry into complex inhaled and respiratory drug delivery. Together, these milestones underscore the Company’s momentum in building a differentiated, high-value respiratory portfolio supported by its state-of-the-art manufacturing platform.